<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drugClass/">Drug classes</a></li>
      </ul>

      <h1>SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS</h1>

      <nav>
        <ul class="nav nav-list">

          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#drugsInClass" data-toggle="tab">Drugs in class</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Selectively inhibit the re-uptake of serotonin (5-hydroxytryptamine, 5-HT).</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturers advise avoid during pregnancy unless the potential benefit outweighs the risk. There is a small increased risk of congenital heart defects when taken during early pregnancy. If used during the third trimester there is a risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn has been reported.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Poorly controlled epilepsy</li>
            <li>SSRIs should not be used if the patient enters a manic phase.</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain (dose-related), constipation (dose-related), diarrhoea (dose-related), dyspepsia (dose-related), gastro-intestinal effects (dose-related), nausea (dose-related), vomiting (dose-related),
              </p>
              <p>
                <strong>uncommon:</strong> Serotonin syndrome,
              </p>
              <p>
                <strong>veryRare:</strong> Angle-closure glaucoma,
              </p>
              <p>
                <strong>notKnown:</strong> Anaphylaxis, angioedema, anorexia with weight loss, anxiety, arthralgia, asthenia, bleeding disorders, convulsions, dizziness, drowsiness, dry mouth, dyskinesias, ecchymoses, galactorrhoea, hallucinations, headache, hypersensitivity reactions, hypomania, hyponatraemia, increased appetite, insomnia, mania, movement disorders, myalgia, nervousness, photosensitivity, purpura, rash, sexual dysfunction, suicidal behaviour, sweating, tremor, urinary retention, urticaria, visual disturbances, weight gain,
              </p>
        
        
            <section class="advice">
                <h3>Hypersensitivity reactions</h3>
              <p>If hypersensitivity reactions (including rash) occur, consider discontinuation&#8212;may be sign of impending serious systemic reaction, possibly associated with vasculitis.</p>
            </section>
            <section class="advice">
                <h3>Hyponatraemia and antidepressant therapy</h3>
              <p>Hyponatraemia (usually in the elderly and possibly due to inappropriate secretion of antidiuretic hormone) has been associated with all types of antidepressants; however, it has been reported more frequently with SSRIs than with other antidepressants. Hyponatraemia should be considered in all patients who develop drowsiness, confusion, or convulsions while taking an antidepressant.</p>
            </section>
            <section class="advice">
                <h3>Suicidal behaviour and antidepressant therapy</h3>
              <p>The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.</p>
            </section>
            <section class="advice">
                <h3>Serotonin syndrome</h3>
              <p>Serotonin syndrome or serotonin toxicity is a relatively uncommon adverse drug reaction caused by excessive central and peripheral serotonergic activity. Onset of symptoms, which range from mild to life-threatening, can occur within hours or days following the initiation, dose escalation, or overdose of a serotonergic drug, the addition of a new serotonergic drug, or the replacement of one serotonergic drug by another without allowing a long enough washout period in-between, particularly when the first drug is an irreversible MAOI or a drug with a long half-life. Severe toxicity, which is a medical emergency, usually occurs with a combination of serotonergic drugs, one of which is generally an MAOI.</p><p>The characteristic symptoms of serotonin syndrome fall into 3 main areas, although features from each group may not be seen in all patients&#8212;neuromuscular hyperactivity (such as tremor, hyperreflexia, clonus, myoclonus, rigidity), autonomic dysfunction (tachycardia, blood pressure changes, hyperthermia, diaphoresis, shivering, diarrhoea), and altered mental state (agitation, confusion, mania).</p><p>Treatment consists of withdrawal of the serotonergic medication and supportive care; specialist advice should be sought.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, nystagmus, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.</p><p>For details on the management of poisoning, see Selective serotonin re-uptake inhibitors, under <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac disease
          </li>
          <li>
            concurrent electroconvulsive therapy
          </li>
          <li>
            diabetes mellitus
          </li>
          <li>
            epilepsy (discontinue if convulsions develop)
          </li>
          <li>
            history of bleeding disorders (especially gastro-intestinal bleeding)
          </li>
          <li>
            history of mania
          </li>
          <li>
            susceptibility to angle-closure glaucoma
          </li>
        </ul>
      </section>





      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in the head, neck, and spine, tinnitus, sleep disturbances, fatigue, influenza-like symptoms, and sweating are the most common features of abrupt withdrawal of an SSRI or marked reduction of the dose; palpitation and visual disturbances can occur less commonly. The dose should be tapered over at least a few weeks to avoid these effects. For some patients, it may be necessary to withdraw treatment over a longer period; consider obtaining specialist advice if symptoms persist.</p>
            </section>
            <section class="treatmentCessation">
              <p>Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).</p>
            </section>
      </section>








      <section class="tab-pane" id="drugsInClass">
        <h2>Drugs in the class of SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS</h2>

          <ul>
            <li><a href="../drug/PHP2421.html">CITALOPRAM</a></li>
            <li><a href="../drug/PHP2424.html">ESCITALOPRAM</a></li>
            <li><a href="../drug/PHP2426.html">FLUOXETINE</a></li>
            <li><a href="../drug/PHP2429.html">FLUVOXAMINE MALEATE</a></li>
            <li><a href="../drug/PHP2432.html">PAROXETINE</a></li>
            <li><a href="../drug/PHP2435.html">SERTRALINE</a></li>
          </ul>
      </section>

    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
</body>
</html>
